EUVIMEDObjevte EUVIMED
KohortenstudieOpen access · CC BY-NC 4.0

Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England

Colin J Crooks iD, Ayan Banerjea iD, James Jones, Caroline Chapman, Simon Oliver, Joe West iD, David J Humes iD

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17632 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2023. Written by Colin J Crooks and 6 co-authors. Institution: Gastrointestinal and Liver Theme, Nottingham Biomedical Research Centre (BRC), Queen's Medical Centre, School of Medicine, National Institute for Hea…. Major MEDLINE topics: Colorectal Neoplasms, Anemia. Cited 24 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

A faecal immunochemical tests (FIT) cut‐off of ≥10 μg Hb/g faeces is now recommended in the UK as a gateway to urgent (suspected cancer) investigation for colorectal cancer (CRC), based on an expected CRC risk threshold of 3%.

Aims

To quantify the risk of CRC at FIT cut‐offs by age, haemoglobin and platelet strata.

Methods

A cohort study of a symptomatic CRC pathway based on primary care FIT tests in Nottingham, UK (November 2017–2021) with 1‐year follow‐up. Heat maps showed the cumulative 1‐year CRC risk using Kaplan–Meier estimates.

Results

In total, 514 (1.5%) CRCs were diagnosed following 33,694 index FIT requests. Individuals with a FIT ≥ 10 μg Hb/g faeces had a >3% risk of CRC, except patients under the age of 40 years (CRC risk 1.45% [95% CI: 0.03%–2.86%]). Non‐anaemic patients with a FIT < 100 μg Hb/g faeces had a CRC risk of

Subjects

MeSH terms (MEDLINE)

Colorectal NeoplasmsAnemiaHumansAgedAged, 80 and overSensitivity and SpecificityCohort StudiesOccult BloodEnglandHemoglobinsColonoscopyFecesPrimary Health CareEarly Detection of Cancer

Author keywords

cancer diagnosiscolorectal cancerdiagnostic testsepidemiologyfaecal immunochemical tests

Substances

Hemoglobins

Authors and institutions

  • Gastrointestinal and Liver Theme, Nottingham Biomedical Research Centre (BRC), Queen's Medical Centre, School of Medicine, National Institute for Health Research (NIHR), Nottingham University Hospitals NHS Trust, Univer…
  • Nottingham Colorectal Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Nottingham Bowel Cancer Screening Hub, School of Medicine, University of Nottingham, Nottingham, UK.
  • Nottingham City Clinical Commissioning Group Nottingham UK, School of Medicine, University of Nottingham, Nottingham, UK.
  • Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID profiles: Colin J Crooks, Ayan Banerjea, Joe West, David J Humes

Cite

APA

Crooks, C. J., Banerjea, A., Jones, J., Chapman, C., Oliver, S., West, J., & Humes, D. J. (2023). Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17632

Vancouver

Crooks CJ, Banerjea A, Jones J, Chapman C, Oliver S, West J, et al. Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17632

BibTeX
@article{Crooks2023,
  author = {Crooks, Colin J and Banerjea, Ayan and Jones, James and Chapman, Caroline and Oliver, Simon and West, Joe and Humes, David J},
  title = {Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17632}
}
Start for free →